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Objective : The aim of this study was to analyze the correlation between thromboembolic complications and antiplatelet drugs before and after
neurointervention.
Methods : Blood samples and radiographic data of patients who received a neurointervention (coil embolization, stent placement or both) were
collected prospectively. Rapid platelet function assay-aspirin (RPFA-ASA) was used to calculate aspirin resistance in aspirin reaction units (ARU).
For clopidogrel resistance, a P2Y12 assay was used to analyze the percentage of platelet inhibition. ARU > 550 and platelet inhibition < 40%
were defined as aspirin and clopidogrel resistance, respectively. 
Results : Both aspirin and clopidogrel oral pills were administered in fifty-three patients before and after neurointerventional procedures. The
mean resistance values of all patients were 484 ARU and < 39%. Ten (17.0%) of 53 patients showed resistance to aspirin with an average of 597
ARU, and 33 (62.3%) of 53 patients showed resistance to clopidogrel with an average of < 26%. Ten patients demonstrated resistance to both
drugs, 5 of which suffered a thromboembolic complication after neurointervention (mean values : 640 ARU and platelet inhibition < 23%).
Diabetic patients and patients with hypercholesterolemia displayed mean aspirin resistances of 513.7 and 501.8 ARU, and mean clopidogrel
resistances of < 33.8% and < 40.7%, respectively. 
Conclusion : Identifying individuals with poor platelet inhibition using standard regimens is of great clinical importance and may help prevent
cerebral ischemic events in the future. Neurointerventional research should focus on ideal doses, timing, choices, safety, and reliable measure-
ments of antiplatelet drug therapy, as well as confirming the clinical relevance of aggregometry in cerebrovascular patients. 
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INTRODUCTION
Recent developments in biomedical devices and pharma-
ceuticals have led to milestones in cerebrovascular neuroin-
tervention. However, thromboembolic events have always
been a major problem in coil embolization of cerebral aneu-
rysms or stent insertions in patients with carotid artery ste-
nosis22). Recently, perioperative aspirin and clopidogrel dual
therapy has been considered as “standard of care” following
the insertion of stents in cerebrovascular disease entities. Anti-
platelet agents such as aspirin and clopidogrel are cor-
nerstones that have allowed and increased the use of mini-
mally invasive treatment of cerebrovascular diseases. Aspirin
irreversibly inhibits full platelet aggregation by inhibiting
cyclooxgenase-1 (COX-1) dependent synthesis of throm-
boxane A2 (TXA2), while clopidogrel, a thienopyridine,
reduces platelet activation by irreversibly blocking ADP
(P2Y12) receptor-dependent pathways11). 
Oral aspirin and/or clopidogrel could reduce unfortunate
thromboembolic events; however, drug resistance to anti-
platelet agents has been a long-term problem that has not yet
to be fully understood11). The term “drug resistance” by
definition is when “a drug is incompetent to reach its phar-
macologic target due to reduced bioavailability, in vivo inacti-
vation, negative interaction with other substances or altera-
tions of the target”4). Aspirin resistance would therefore mean
the inability to inhibit COX-1-dependent TXA2 production
and its byproducts. Clopidogrel resistance occurs along with
variations in its absorption, metabolism, and genetic varia-
tions in the P2Y12 receptor3).
This study investigated aspirin and clopidogrel resistance
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rates of patients medicated prior to and after a neurointer-
vention, including those who suffered thromboembolic
complications.
MATERIALS AND METHODS
A prospective study was done on 53 patients (24 male, 29
female) from January 2007 to July 2008. All patients receiv-
ed either a coil embolization, stent insertion, or both for :
intracranial arterial stenosis (7 patients), carotid arterial steno-
sis (15 patients), cerebrovascular dissection (3 patients), and
intracranial aneurysm (28 patients). Eleven (39.3%) of 28
patients with aneurysms received coil embolization without
balloon or stent, while 17 patients received stent-assisted
coiling. The remaining patients were treated with stents only.
All patients were pre-medicated with 100mg of aspirin and
75 mg of clopidogrel for at least 72 hours before the proce-
dure. An aspirin/clopidogrel resistance test based on phar-
maceutical doses was conducted after taking the medicine for
3 days. Clinical and angiographic examinations were done
before and 6 months after the intervention. 
Endovascular procedures
Endovascular procedures were carried out under general
anesthesia in 28 (52.8%) of the 53 patients and under seda-
tion in 8 (15.0%) of them. Arterial access was achieved via
the femoral artery in all patients. A bolus of heparin was
administered with 5,000 IU, maintaining the clotting time
during the procedure at no more than 250 seconds during
the procedure. A guiding catheter was placed in the internal
carotid artery. We used an A 6-F guiding catheter system
(Envoy; Codman Neurovascular, Miami Lakes, FL, USA)
through the femoral artery via the vascular sheath. Cerebral
angiography was done using this guiding catheter with he-
parin infusion (clotting time between 250 to 300 seconds)
during the intervention. Then a microcatheter (Excelsior SL-
10; Boston Scientific, Natick, MA, USA; Echelon-10; ev3,
Irvine, CA, USA) was advanced and placed into the aneu-
rysm using Synchro and Agility 0.014-inch microwires (Bos-
ton Scientific, Natick, MA, USA) via conventional technique.
We also used two-types of self-expandable stents (Neuroform
3; Boston Scientific, Natick, MA, USA; Enterprise stent;
Codman Neurovascular, Miami, FL, USA), Guglielmi deta-
chable coils (GDCs; Boston Scientific), and other bare plati-
num coils (MicroPlex; Microvention, Aliso Viejo, CA, USA;
Trufill-DCS; Codman Neurovascular, Miami Lakes, FL,
USA) for aneurysms. For the stenting procedure, placement
of the embolic protection device into a distal artery occurred
after advancement of a Shuttle catheter (Cook : Bloomington,
IN, USA). Balloon dilatation was optional. Stent insertion
was carried out using the following stents : Precise (Codman
Neurovascular, Miami, FL, USA), Protege (ev3, Irvine, CA,
USA) and Wallstent (Boston Scientific, Natick, MAM USA).
Vascular accesses were sealed up using the Angio-Seal closure
device (St. Jude Medical, Minnetonka, MN, USA).
Assessments of drug resistance
VerifyNow Rapid platelet function assay-aspirin (RPFA-
ASA) (Accumetrics, San Diego, CA, USA) was used to cal-
culate aspirin resistance in aspirin reaction units (ARU). The
VerifyNow P2Y12 assay (Accumetrics, San Diego, CA, USA)
was used to analyze the percentage of platelet inhibition for
clopidogrel resistance. ARU > 550 and a platelet inhibition
< 40% were defined as aspirin and clopidogrel resistance,
respectively. 
Statistical analysis
Statistical analyses were done using commercial software
(SPSS, version 15.0, SPSS Inc.) Uni- (Fisher’s exact test) and
multi-variate (binary logistic regression) analysis were used to
explore associations of variable factors with aspirin and/or
clopidogrel resistance. Statistical analysis on the correlations
between complication occurrence and aspirin (> 550) and
clopidogrel resistance (< 40%) were performed using the
Mann-Whitney U test. p values < 0.05 were considered sta-
tistically significant.
RESULTS
Patients ranged in age from 52 to 81 years (mean ± SD;
60.3 ± 12 years), including 24 male and 29 female patients.
Thirteen patients were diabetic and 10 had hypercholesterol-
emia. Mean follow-up period was 18.2 ± 7.84 months.
Mean drug resistance levels for all patients were 484 ± 85.6
ARU for aspirin and < 39 ± 20.1% for clopidogrel. Ten
patients (17%) showed resistance to aspirin (597 ± 80.97
ARU), 33 patients (62.3%) to clopidogrel (< 26 ± 10.35%),
and 10 patients (17%) were resistant to both drugs. 
There were 5 (9.4%) cases of thromboembolic compli-
cations (2 embolic and 3 thrombotic), and all 5 showed resis-
tance to both agents (640 ± 34.8 ARU for aspirin and < 23 ±
2.3% for clopidogrel). The remaining 48 non-complicated
patients had drug resistance levels of 468 ± 71.8 ARU for
aspirin and < 40 ± 20.4% for clopidogrel. Only 5 non-com-
plicated patients (10.4%) were aspirin resistant, while 28
(52.8%) presented with clopidogrel resistance.
In the diabetic subgroup, aspirin resistance was 513.7 ±
102.54 ARU and clopidogrel resistance was < 33.8%. For
patients with hypercholesterolemia, means of 501.8 ± 93.81
ARU for aspirin and < 40.7% for clopidogrel were measured.
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Of the 13 patients with diabetes, 3
(23%) presented with complications,
while 3 (30%) of the 10 patients with
hypercholesterolemia experienced a
thromboembolic event.
In this study, uni- and multi-variate
analysis revealed that smoking was the
only factor associated with aspirin resis-
tance (p = 0.005 and 0.006, respecti-
vely), while hypercholesterolemia was
the only factor associated with clopido-
grel resistance (p = 0.030 and 0.028,
respectively) (Table 1, 2).
Associations between the occurrence
of post-procedural complications and
each aspirin and/or clopidogrel resis-
tance levels were analyzed. Mean aspirin
resistance levels with and without com-
plication were 630 (range, 587-679)
and 468.5 (range, 318-646), respecti-
vely (p = 0.003). Clopidogrel resistance
levels with and without post-procedu-
ral complication were 23 (range : 21-
27) and 35 (range : 16-91), respectively
(p = 0.010) (Table 3).
DISCUSSION
The ultimate goal of cerebrovascular
diseases is to keep cerebrovascular
blood flow hemodynamically stable so
that no occlusion or hemorrhage oc-
curs31). Self-expandable stents, there-
fore, are used after a coil embolization
in order to maintain cerebral blood
flow. The insertion of a bare metal
stent or coil has always required the
need for anti-thrombotic agents to pre-
vent thrombosis and occlusion24). Thr-
ombotic agents such as anti-coagulants
(heparin and warfarin), anti-platelet
drugs (aspirin, clopidogrel, and dipyri-
damole), and thrombolytics have been
used for more than 2 decades23). In general, antiplatelet
agents are considered most beneficial for thrombotic strokes
and anticoagulants are most effective for cardio-embolic
strokes1). Overdosage with these agents, however, increases
risk of hemorrhage. Therefore, careful dosing is needed. Find-
ing the optimal dosage to reach suitable therapeutic levels has
been difficult because of drug resistance.
According to previous clinical trial, clopidogrel resistance is
more frequent than aspirin resistance16,25). In a study by Lee
et al.14), poor response to clopidogrel was quite prevalent
(42.9%), whereas just a few patients had poor response to
aspirin (2%). Mean clopidogrel resistance of all patients (39
± 20.1%) was also high in this study, compared to aspirin
(484 ± 85.6 ARU), supporting the reason why more than
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Table 1. Univariate and multivariate analysis of the correlation between variable factors and aspirin
resistance
Variables
Aspirin resistance (ARU > 550) Univariate Multivariate
(+) (-) p-value p-value
Age 0.293 0.188
> 68 7 (70.0%) 20 (46.5%)
≤ 68 3 (30.0%) 23 (53.5%)
Gender 0.741 0.115
M 6 (60.0%) 23 (53.5%)
F 4 (40.0%) 20 (46.5%)
Diabetes 0.692 0.514
(+) 3 (30.0%) 10 (23.3%)
(-) 7 (70.0%) 33 (76.7%)
Hypercholesterolemia 1.000 0.794
(+) 2 (20.0%) 8 (18.6%)
(-) 8 (80.0%) 35 (81.4%)
Hypertension 0.374 0.420
(+) 5 (50.0%) 28 (65.1%)
(-) 5 (50.0%) 15 (34.9%)
Smoking 0.005 0.006
(+) 9 (0.0%) 17 (39.5%)
(-) 1 (10.0%) 26 (60.5%)
Table 2. Univariate and multivariate analysis of the correlation between variable factors and clopi-
dogrel resistance
Variables
Clopidogrel resistance (< 40%) Univariate Multivariate
(+) (-) p-value p-value
Age 0.915 0.894
> 68 17 (51.5%) 10 (50.0%)
≤ 68 16 (48.5%) 10 (50.0%)
Gender 0.974 0.908
M 18 (54.5%) 11 (55.0%)
F 15 (45.5%) 9 (45.0%)
Diabetes 0.950 0.767
(+) 8 (24.2%) 5 (25.0%)
(-) 25 (75.8%) 15 (75.0%)
Hypercholesterolemia 0.030 0.028
(+) 2 (9.1%) 8 (35.0%)
(-) 7 (90.9%) 36 (65.0%)
Hypertension 0.396 0.419
(+) 22 (66.7%) 11 (55.0%)
(-) 11 (33.3%) 9 (45.0%)
Smoking 0.915 0.983
(+) 16 (48.5%) 10 (50.0%)
(-) 17 (51.5%) 10 (50.0%)
half of the patients (62.3%) in the study showed clopidogrel
resistance. Aspirin inhibits serum thromboxane B2 up to 95%,
and resistance implies less sensitive inactivation of cyclooxy-
genase-1, whereas clopidogrel is highly variable and reflects
the bioavailability of the active metabolite, not “resistance” of
the receptor to inhibition10). Extrinsic factors (patient non-
compliance, underdosing, drug interactions, and variability
in intestinal absorption/hepatic metabolism), patient con-
ditions (diabetes and hypercholesterolemia) that increase
platelet reactivity, and intrinsic factors (variability in P2Y12
receptor affinity and binding properties) also contribute to
clopidogrel resistance13,33).
The percentage of our patients with aspirin resistance was
similar to those with resistance to both aspirin and clopido-
grel. This could be explained by the association of aspirin
resistance with platelet hyper-reactivity16), collagen, and ade-
nosine diphosphate (ADP) sensitivity30). In one study, 50% of
patients with aspirin resistance were also resistant to clopido-
grel, while only about 20% of aspirin-sensitive patients were
resistant to clopidogrel20). Aspirin-resistant patients displayed
a reduced degree of platelet aggregation, P-selectin expres-
sion, and less inhibition of GP IIb/IIIa receptor activation in
response to clopidogrel16).
In our study, all patients with a complication after neuroin-
tervention displayed resistance to both aspirin and clopidog-
rel. These patients may have unpredictable heritable factors,
indirectly related to platelet cyclooxygenase inactivation, and
bioavailability of clopidogrel susceptible to drug resistance10). 
The patient group with diabetes and hypercholesterolemia
showed resistance to aspirin (513.7, 501.8 ARU), but only
the diabetic group revealed resistant to clopidogrel (< 33.8%).
Diabetes plays a role in decreasing the effectiveness of anti-
platelet agents by producing reactive oxidant species6), in-
creases platelet aggregation, activation2) by insulin resistance
and increases P2Y12 signaling9), increases platelet turnover,
alteres platelet membrane structure, increases intracellular cal-
cium, and abnormal glycation17,28,32). These mechanisms could
explain why diabetics were more clopidogrel resistant than
hypercholesterolemia in our study. Prabhakaran et al.22), found
multivariable models of diabetes were independently predic-
tive of poor platelet inhibition in clopidogrel-treated patients.
Likewise, hypercholesterolemia attenuates aspirin’s effect on
thrombin27). Similar to diabetes, hyper-
cholesterolemia is a pathophysiological
condition that promotes atherosclerosis,
thus increasing oxygen-free radicals
and isoprostane levels8) that contribute
to aspirin resistance6).
Previous studies have suggested a
strong association of smoking with as-
pirin resistance19). Our analysis also revealed correlation of
smoking with aspirin resistance. Although our results show
different result to the existing researches, smoking has been
thought to have a “paradoxical effect” with clopidogrel. In-
terestingly, recent studies reported that cigarette smoking is one
of the factors associated with a prompt antiplatelet response
to clopidogrel5).
Although recent clinical trials have shown a protocol using
the “dual therapy” of aspirin and clopidogrel to prevent throm-
botic and embolic complication during/after a neurointer-
vention18,26,35), antithrombotic therapy still remains an unpro-
ven benefit in many clinical settings of cerebrovascular disea-
se23). This elicited the need for monitoring the response to
anti-platelet agents to help elucidate the problem of drug
resistance. Currently, there are several suggested drug regi-
mens. First of all, extrinsic factors can be modified. Non-
compliance of the patient can be monitored thoroughly7).
And, increasing dosage of aspirin and clopidogrel can shorten
duration of antiplatelet therapy. For example, increasing the
loading dose from 300 mg to 600 mg or changing the main-
tenance dose from 75 mg to 150 mg lowered the frequency
of clopidogrel resistance29), though this may be associated
with a higher bleeding risk12). Short-term administration of
dual therapy resulted in a relatively stable level of inhibition14).
Avoiding the use of non-steroidal anti-inflammatory drugs
(competitor of COX inhibition) with aspirin could also help
avoid aspirin resistance. Secondly, the medical condition of
patients can be controlled beforehand. Diabetes regulated on
a daily basis and a low-fat diet with more exercise decreased
blood cholesterol levels. Thirdly, measurement of resistance
level should be standardized. At the present time, many labo-
ratory methods are used to measure aspirin and clopidogrel
resistance. However, results can be different according to me-
thod of measurement. Unified and verified testing is needed.
Finally, administering a whole new anti-platelet drug or sup-
plementing an additional anti-platelet agent to conventional
dual therapy, is recommended. New anti-platelet agents,
known as CS-747 (Prasugrel), intravenous P2Y12 inhibitor
agent (Cangrelor)21), and oral ADP antagonist (AZD6140)
are now in clinical trials34); in particular, triple anti-platelet
therapy with the addition of Cilostazol is thought to be better
in preventing stent thrombosis than conventional treatment15).
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Table 3. The correlation between post-procedural complication and each resistance of aspirin and
clopidogrel
Aspirin resistance level Clopidogrel resistance level
Median (range) Median (range)
Complication
(+) 630 (587-679) 23 (21-27)
(-) 468.5 (318-646) 35 (16-91)
p-value 0.003 0.010
Cilostazol is a selective inhibitor of phosphodiesterase type 3.
This action results in increased cyclic adenosine monopho-
sphate (cAMP). An increase in cAMP causes an increase in
the active form of protein kinase A, which is associated with
an inhibition of platelet aggregation. Many studies have sug-
gested not only efficacy but also safety of cilostazol. As a result,
cilostazol has been in the spotlight for combination therapy
with aspirin and clopidogrel.
CONCLUSION
Identifying individuals with poor platelet inhibition using
standard regimens may be of great clinical importance and
will help prevent cerebral ischemic events in the future. Neu-
rointerventional research should focus on optimal doses, tim-
ing, choices, safety, and reliable measurement of antiplatelet
drug therapy, as well as confirming the clinical relevance of
aggregometry in cerebrovascular patients.
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